Division of Cardiovascular Diseases, University of Alabama at Birmingham, Birmingham, AL 35294-0007, USA.
J Clin Hypertens (Greenwich). 2010 Jan;12(1):3-13. doi: 10.1111/j.1751-7176.2009.00217.x.
Demographic factors are known to influence the prevalence of hypertension, and evidence suggests that they may also influence the response of patients with hypertension to blood pressure (BP)-lowering therapies. To determine the effect of demographic factors on the efficacy and safety of an olmesartan medoxomil (OM)-based treatment regimen, we performed a prespecified subgroup analysis of a 12-week, randomized, placebo-controlled, titrate-to-goal study in patients with hypertension, stratifying patients into treatment groups according to age, sex, or race. After 12 weeks, OM-based therapy significantly reduced BP from baseline in blacks, non-blacks, men, women, and patients younger than 65 or 65 years and older compared with placebo, and enabled 51.9% to 79.5% of patients to achieve a BP goal of <140/90 mm Hg. The differences in BP-lowering efficacy of OM-based therapy between subgroups were not clinically significant, and treatment was generally well tolerated in all groups. This study demonstrates that an OM-based treatment algorithm is an effective and safe option for achieving recommended BP goal in patients with hypertension including blacks, non-blacks, men, women, and patients younger than 65 or 65 years and older.
人口统计学因素已知会影响高血压的患病率，有证据表明，这些因素也可能影响高血压患者对降压治疗的反应。为了确定人口统计学因素对奥美沙坦酯（OM）为基础的治疗方案疗效和安全性的影响，我们对一项为期 12 周、随机、安慰剂对照、滴定至目标的高血压患者研究进行了预先设定的亚组分析，根据年龄、性别或种族将患者分层到治疗组。经过 12 周，与安慰剂相比，OM 为基础的治疗方案显著降低了黑人、非黑人、男性、女性以及年龄小于 65 岁或大于 65 岁的患者的血压，使 51.9%至 79.5%的患者达到了<140/90mmHg 的血压目标。OM 为基础的治疗方案在亚组之间的降压疗效差异无临床意义，并且在所有组中治疗总体上均耐受良好。这项研究表明，基于 OM 的治疗方案是一种有效且安全的选择，可使包括黑人、非黑人、男性、女性以及年龄小于 65 岁或大于 65 岁的高血压患者达到推荐的血压目标。
